349 related articles for article (PubMed ID: 32601915)
1. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
Shirley M
Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
[TBL] [Abstract][Full Text] [Related]
2. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Abed Y; Saim-Mamoun A; Boivin G
Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
[TBL] [Abstract][Full Text] [Related]
3. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
[TBL] [Abstract][Full Text] [Related]
5. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
6. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor.
Todd B; Tchesnokov EP; Götte M
J Biol Chem; 2021; 296():100486. PubMed ID: 33647314
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
[TBL] [Abstract][Full Text] [Related]
8. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
[TBL] [Abstract][Full Text] [Related]
9. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
10. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
11. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.
Ince WL; Smith FB; O'Rear JJ; Thomson M
J Infect Dis; 2020 Aug; 222(6):957-961. PubMed ID: 32253432
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
Taniguchi K; Ando Y; Kobayashi M; Toba S; Nobori H; Sanaki T; Noshi T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062315
[TBL] [Abstract][Full Text] [Related]
14. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
[TBL] [Abstract][Full Text] [Related]
15. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
[TBL] [Abstract][Full Text] [Related]
16. Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition.
Jones JC; Pascua PNQ; Harrington WN; Webby RJ; Govorkova EA
J Antimicrob Chemother; 2021 Mar; 76(4):957-960. PubMed ID: 33351916
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
[TBL] [Abstract][Full Text] [Related]
18. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
19. Xofluza Now Indicated to Prevent Influenza.
Aschenbrenner DS
Am J Nurs; 2021 Feb; 121(2):26-27. PubMed ID: 33497124
[TBL] [Abstract][Full Text] [Related]
20. Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
Patel MC; Mishin VP; De La Cruz JA; Chesnokov A; Nguyen HT; Wilson MM; Barnes J; Kondor RJG; Wentworth DE; Gubareva LV
Antiviral Res; 2020 Oct; 182():104906. PubMed ID: 32798601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
